SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Cardiovascular

PUBLISHER: Market Glass, Inc. | PRODUCT CODE: 2148458

Cover Image

PUBLISHER: Market Glass, Inc. | PRODUCT CODE: 2148458

Acute Heart Failure (AHF) Therapeutics

PUBLISHED:
PAGES: 331 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF & Excel (Single User License)
USD 5850
PDF & Excel (Team License: Up to 10 users)
USD 11115
PDF & Excel (Global License to Company and its Fully-owned Subsidiaries)
USD 17550

Add to Cart

Description

Table of Contents

Global Acute Heart Failure (AHF) Therapeutics Market to Reach US$6.3 Million by 2032

The global market for Acute Heart Failure (AHF) Therapeutics estimated at US$3.7 Million in the year 2025, is expected to reach US$6.3 Million by 2032, growing at a CAGR of 8.0% over the analysis period 2025-2032. Angiotensin-Converting Enzyme Inhibitors Drug Class, one of the segments analyzed in the report, is expected to record a 10.5% CAGR and reach US$1.7 Million by the end of the analysis period. Growth in the Angiotensin II Receptor Blockers Drug Class segment is estimated at 5.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.0 Million While China is Forecast to Grow at 12.6% CAGR

The Acute Heart Failure (AHF) Therapeutics market in the U.S. is estimated at US$1.0 Million in the year 2025. China, the world's second largest economy, is forecast to reach a projected market size of US$1.4 Million by the year 2032 trailing a CAGR of 12.6% over the analysis period 2025-2032. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.1% and 7.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.6% CAGR.

Acute Heart Failure (AHF) Therapeutics - Key Trends and Drivers

Acute heart failure (AHF) is a critical condition marked by the sudden onset of heart failure symptoms or the worsening of existing heart conditions, posing severe health risks due to the heart's inability to pump sufficient blood. This medical emergency, involving systemic congestion and potential organ dysfunction, requires immediate and effective management strategies to ensure patient survival and maintain quality of life. The complexity of AHF's pathophysiology, which can stem from a variety of cardiac abnormalities, complicates its treatment and highlights the necessity of differentiated approaches for its two main forms: de novo heart failure and acutely decompensated heart failure. While the former demands a comprehensive diagnosis to identify the underlying cardiac issue in patients with no prior history of heart disease, the latter focuses on managing the abrupt deterioration of an existing chronic condition.

Treatment protocols for AHF emphasize managing symptoms and addressing the root causes of the heart's reduced functionality. Initial strategies typically include non-invasive ventilation and rapid administration of diuretics to alleviate fluid overload, which is a common complication of AHF. Alongside these, other therapeutic interventions such as vasodilators are used to reduce cardiac load in patients with stable blood pressure, while inotropic support is reserved for severe cases to maintain hemodynamic stability. Additionally, the use of anticoagulants is recommended to prevent thromboembolic events in susceptible patients, underscoring the importance of a balanced approach that considers both efficacy and safety. Moreover, an early post-discharge follow-up is crucial for optimizing long-term management and reducing the chances of hospital readmission, reflecting a proactive approach to patient care that extends beyond the initial treatment phase.

The landscape of AHF therapeutics is evolving, driven by several growth factors including technological advancements in diagnostics, increased adoption of remote patient monitoring, and greater patient awareness and education about heart failure. Innovations in cardiac imaging and biomarker diagnostics enhance the precision of AHF detection and monitoring, facilitating timely and personalized treatment interventions. Additionally, the integration of artificial intelligence and machine learning in healthcare systems is revolutionizing AHF therapy by improving the accuracy of patient assessments and optimizing treatment protocols. The development of novel pharmaceuticals and expansion of treatment modalities, such as gene therapy and biologics, are broadening the spectrum of therapeutic options available, appealing to a diverse patient population and healthcare providers. Moreover, changes in the regulatory and reimbursement landscape are encouraging the adoption of advanced, albeit often expensive, treatments. As AHF continues to be a major cause of hospital readmission and mortality, these factors collectively contribute to the dynamic advancement and adoption of new therapeutic strategies, shaping the future of AHF management.

SCOPE OF STUDY:

The report analyzes the Acute Heart Failure (AHF) Therapeutics market by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Class (Angiotensin-Converting Enzyme Inhibitors Drug Class, Angiotensin II Receptor Blockers Drug Class, Beta-Blockers Drug Class, Diuretics Drug Class, Vasodilators Drug Class, Recombinant Human B-Type Natriuretic Peptide Drug Class, Selective Aldosterone Receptor Antagonists Drug Class); Therapy (Emergency Care Therapy, Short-Term Therapy); Administration Route (Oral Administration Route, Intravenous Administration Route, Subcutaneous Administration Route)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

SELECT PLAYERS -

  • Bayer AG
  • Bristol-Myers Squibb Company
  • Cardiorentis AG
  • CVie Therapeutics Limited
  • Cytokinetics, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Orion Corporation
  • PhaseBio Pharmaceuticals, Inc.

WHAT SETS THIS REPORT APART FROM OTHERS?

Grounded in Domain Expert Perspectives - Incorporates perspectives emerging from domain experts across industry, enterprise and academia, adding context beyond conventional published research.

Captures Early Market Signals - Tracks shifts emerging through expert conversations, company activity and market-relevant discussions before they are fully reflected in traditional secondary research.

Draws From a Broad, Validated Intelligence Base - Brings together insights from conference sessions, keynotes, panel discussions, blogs, corporate disclosures, annual reports, institutional publications and other validated sources.

Connects Signals With Strategic Market Direction - Synthesizes these perspectives to identify where the market is moving, what is driving that movement and which developments are likely to matter most for strategy.

Provides In-Depth Company Intelligence - Extends beyond market-level analysis to examine the companies participating in and shaping the competitive environment.

Market Share Is Examined Where It Matters - A single global market share figure rarely tells the full story. Competitive structures can vary significantly across geographies. Where analytically relevant, Market Glass reports extend market share analysis into major regions with the level of detail tailored to the structure and dynamics of each market.

Show more
Product Code: MG6845

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy
    • Global Economic Update
    • Acute Heart Failure (AHF) Therapeutics - Global Key Competitors Percentage Market Share in 2026 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for 93 Players Worldwide in 2026 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Advances in Diagnostic Tools Propel Growth
    • Novel Drug Development Expands Addressable Market Opportunity
    • Personalized Medicine Strengthens Business Case for Targeted Therapies
    • Aging Population and Increasing Incidence Rates Drive Demand
    • Technological Innovations in Drug Delivery Systems Accelerate Market Growth
    • Regulatory Approvals for New Therapies Spur Market Expansion
    • Increased Healthcare Expenditure Sustains Growth
    • Rising Awareness and Early Diagnosis Generate Demand
    • Integration of AI and Big Data in Clinical Trials Throws the Spotlight on Precision Medicine
    • Increasing Use of Biomarkers in AHF Diagnosis and Treatment Generates Demand
    • Telemedicine and Remote Monitoring Solutions Propel Market Growth
    • Evolution of Value-Based Care Models Spurs Demand for Effective AHF Therapies
    • Expansion of Biopharmaceutical Industry Boosts Innovation in AHF Therapeutics
    • Advances in Genetic Research and Genomics Strengthen Personalized Treatment Approaches
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Acute Heart Failure (AHF) Therapeutics Market Analysis of Annual Sales in US$ Thousand for Years 2020 through 2032
    • TABLE 2: World Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
    • TABLE 3: World 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2026 & 2032
    • TABLE 4: World Recent Past, Current & Future Analysis for Angiotensin-Converting Enzyme Inhibitors Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
    • TABLE 5: World 8-Year Perspective for Angiotensin-Converting Enzyme Inhibitors Drug Class by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2026 & 2032
    • TABLE 6: World Recent Past, Current & Future Analysis for Angiotensin II Receptor Blockers Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
    • TABLE 7: World 8-Year Perspective for Angiotensin II Receptor Blockers Drug Class by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2026 & 2032
    • TABLE 8: World Recent Past, Current & Future Analysis for Beta-Blockers Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
    • TABLE 9: World 8-Year Perspective for Beta-Blockers Drug Class by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2026 & 2032
    • TABLE 10: World Recent Past, Current & Future Analysis for Diuretics Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
    • TABLE 11: World 8-Year Perspective for Diuretics Drug Class by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2026 & 2032
    • TABLE 12: World Recent Past, Current & Future Analysis for Vasodilators Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
    • TABLE 13: World 8-Year Perspective for Vasodilators Drug Class by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2026 & 2032
    • TABLE 14: World Recent Past, Current & Future Analysis for Recombinant Human B-Type Natriuretic Peptide Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
    • TABLE 15: World 8-Year Perspective for Recombinant Human B-Type Natriuretic Peptide Drug Class by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2026 & 2032
    • TABLE 16: World Recent Past, Current & Future Analysis for Selective Aldosterone Receptor Antagonists Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
    • TABLE 17: World 8-Year Perspective for Selective Aldosterone Receptor Antagonists Drug Class by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2026 & 2032
    • TABLE 18: World Recent Past, Current & Future Analysis for Emergency Care Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
    • TABLE 19: World 8-Year Perspective for Emergency Care Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2026 & 2032
    • TABLE 20: World Recent Past, Current & Future Analysis for Short-Term Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
    • TABLE 21: World 8-Year Perspective for Short-Term Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2026 & 2032
    • TABLE 22: World Recent Past, Current & Future Analysis for Oral Administration Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
    • TABLE 23: World 8-Year Perspective for Oral Administration Route by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2026 & 2032
    • TABLE 24: World Recent Past, Current & Future Analysis for Intravenous Administration Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
    • TABLE 25: World 8-Year Perspective for Intravenous Administration Route by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2026 & 2032
    • TABLE 26: World Recent Past, Current & Future Analysis for Subcutaneous Administration Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
    • TABLE 27: World 8-Year Perspective for Subcutaneous Administration Route by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2026 & 2032

III. MARKET ANALYSIS

  • UNITED STATES
    • Acute Heart Failure (AHF) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2026 (E)
    • TABLE 28: USA Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Drug Class - Angiotensin-Converting Enzyme Inhibitors Drug Class, Angiotensin II Receptor Blockers Drug Class, Beta-Blockers Drug Class, Diuretics Drug Class, Vasodilators Drug Class, Recombinant Human B-Type Natriuretic Peptide Drug Class and Selective Aldosterone Receptor Antagonists Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 29: USA 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Angiotensin-Converting Enzyme Inhibitors Drug Class, Angiotensin II Receptor Blockers Drug Class, Beta-Blockers Drug Class, Diuretics Drug Class, Vasodilators Drug Class, Recombinant Human B-Type Natriuretic Peptide Drug Class and Selective Aldosterone Receptor Antagonists Drug Class for the Years 2026 & 2032
    • TABLE 30: USA Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Therapy - Emergency Care Therapy and Short-Term Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 31: USA 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Therapy - Percentage Breakdown of Value Sales for Emergency Care Therapy and Short-Term Therapy for the Years 2026 & 2032
    • TABLE 32: USA Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Administration Route - Oral Administration Route, Intravenous Administration Route and Subcutaneous Administration Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 33: USA 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Intravenous Administration Route and Subcutaneous Administration Route for the Years 2026 & 2032
  • CANADA
    • TABLE 34: Canada Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Drug Class - Angiotensin-Converting Enzyme Inhibitors Drug Class, Angiotensin II Receptor Blockers Drug Class, Beta-Blockers Drug Class, Diuretics Drug Class, Vasodilators Drug Class, Recombinant Human B-Type Natriuretic Peptide Drug Class and Selective Aldosterone Receptor Antagonists Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 35: Canada 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Angiotensin-Converting Enzyme Inhibitors Drug Class, Angiotensin II Receptor Blockers Drug Class, Beta-Blockers Drug Class, Diuretics Drug Class, Vasodilators Drug Class, Recombinant Human B-Type Natriuretic Peptide Drug Class and Selective Aldosterone Receptor Antagonists Drug Class for the Years 2026 & 2032
    • TABLE 36: Canada Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Therapy - Emergency Care Therapy and Short-Term Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 37: Canada 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Therapy - Percentage Breakdown of Value Sales for Emergency Care Therapy and Short-Term Therapy for the Years 2026 & 2032
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Administration Route - Oral Administration Route, Intravenous Administration Route and Subcutaneous Administration Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 39: Canada 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Intravenous Administration Route and Subcutaneous Administration Route for the Years 2026 & 2032
  • JAPAN
    • Acute Heart Failure (AHF) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2026 (E)
    • TABLE 40: Japan Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Drug Class - Angiotensin-Converting Enzyme Inhibitors Drug Class, Angiotensin II Receptor Blockers Drug Class, Beta-Blockers Drug Class, Diuretics Drug Class, Vasodilators Drug Class, Recombinant Human B-Type Natriuretic Peptide Drug Class and Selective Aldosterone Receptor Antagonists Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 41: Japan 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Angiotensin-Converting Enzyme Inhibitors Drug Class, Angiotensin II Receptor Blockers Drug Class, Beta-Blockers Drug Class, Diuretics Drug Class, Vasodilators Drug Class, Recombinant Human B-Type Natriuretic Peptide Drug Class and Selective Aldosterone Receptor Antagonists Drug Class for the Years 2026 & 2032
    • TABLE 42: Japan Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Therapy - Emergency Care Therapy and Short-Term Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 43: Japan 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Therapy - Percentage Breakdown of Value Sales for Emergency Care Therapy and Short-Term Therapy for the Years 2026 & 2032
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Administration Route - Oral Administration Route, Intravenous Administration Route and Subcutaneous Administration Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 45: Japan 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Intravenous Administration Route and Subcutaneous Administration Route for the Years 2026 & 2032
  • CHINA
    • Acute Heart Failure (AHF) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2026 (E)
    • TABLE 46: China Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Drug Class - Angiotensin-Converting Enzyme Inhibitors Drug Class, Angiotensin II Receptor Blockers Drug Class, Beta-Blockers Drug Class, Diuretics Drug Class, Vasodilators Drug Class, Recombinant Human B-Type Natriuretic Peptide Drug Class and Selective Aldosterone Receptor Antagonists Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 47: China 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Angiotensin-Converting Enzyme Inhibitors Drug Class, Angiotensin II Receptor Blockers Drug Class, Beta-Blockers Drug Class, Diuretics Drug Class, Vasodilators Drug Class, Recombinant Human B-Type Natriuretic Peptide Drug Class and Selective Aldosterone Receptor Antagonists Drug Class for the Years 2026 & 2032
    • TABLE 48: China Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Therapy - Emergency Care Therapy and Short-Term Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 49: China 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Therapy - Percentage Breakdown of Value Sales for Emergency Care Therapy and Short-Term Therapy for the Years 2026 & 2032
    • TABLE 50: China Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Administration Route - Oral Administration Route, Intravenous Administration Route and Subcutaneous Administration Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 51: China 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Intravenous Administration Route and Subcutaneous Administration Route for the Years 2026 & 2032
  • EUROPE
    • Acute Heart Failure (AHF) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2026 (E)
    • TABLE 52: Europe Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
    • TABLE 53: Europe 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2026 & 2032
    • TABLE 54: Europe Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Drug Class - Angiotensin-Converting Enzyme Inhibitors Drug Class, Angiotensin II Receptor Blockers Drug Class, Beta-Blockers Drug Class, Diuretics Drug Class, Vasodilators Drug Class, Recombinant Human B-Type Natriuretic Peptide Drug Class and Selective Aldosterone Receptor Antagonists Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 55: Europe 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Angiotensin-Converting Enzyme Inhibitors Drug Class, Angiotensin II Receptor Blockers Drug Class, Beta-Blockers Drug Class, Diuretics Drug Class, Vasodilators Drug Class, Recombinant Human B-Type Natriuretic Peptide Drug Class and Selective Aldosterone Receptor Antagonists Drug Class for the Years 2026 & 2032
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Therapy - Emergency Care Therapy and Short-Term Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 57: Europe 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Therapy - Percentage Breakdown of Value Sales for Emergency Care Therapy and Short-Term Therapy for the Years 2026 & 2032
    • TABLE 58: Europe Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Administration Route - Oral Administration Route, Intravenous Administration Route and Subcutaneous Administration Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 59: Europe 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Intravenous Administration Route and Subcutaneous Administration Route for the Years 2026 & 2032
  • FRANCE
    • Acute Heart Failure (AHF) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2026 (E)
    • TABLE 60: France Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Drug Class - Angiotensin-Converting Enzyme Inhibitors Drug Class, Angiotensin II Receptor Blockers Drug Class, Beta-Blockers Drug Class, Diuretics Drug Class, Vasodilators Drug Class, Recombinant Human B-Type Natriuretic Peptide Drug Class and Selective Aldosterone Receptor Antagonists Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 61: France 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Angiotensin-Converting Enzyme Inhibitors Drug Class, Angiotensin II Receptor Blockers Drug Class, Beta-Blockers Drug Class, Diuretics Drug Class, Vasodilators Drug Class, Recombinant Human B-Type Natriuretic Peptide Drug Class and Selective Aldosterone Receptor Antagonists Drug Class for the Years 2026 & 2032
    • TABLE 62: France Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Therapy - Emergency Care Therapy and Short-Term Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 63: France 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Therapy - Percentage Breakdown of Value Sales for Emergency Care Therapy and Short-Term Therapy for the Years 2026 & 2032
    • TABLE 64: France Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Administration Route - Oral Administration Route, Intravenous Administration Route and Subcutaneous Administration Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 65: France 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Intravenous Administration Route and Subcutaneous Administration Route for the Years 2026 & 2032
  • GERMANY
    • Acute Heart Failure (AHF) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2026 (E)
    • TABLE 66: Germany Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Drug Class - Angiotensin-Converting Enzyme Inhibitors Drug Class, Angiotensin II Receptor Blockers Drug Class, Beta-Blockers Drug Class, Diuretics Drug Class, Vasodilators Drug Class, Recombinant Human B-Type Natriuretic Peptide Drug Class and Selective Aldosterone Receptor Antagonists Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 67: Germany 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Angiotensin-Converting Enzyme Inhibitors Drug Class, Angiotensin II Receptor Blockers Drug Class, Beta-Blockers Drug Class, Diuretics Drug Class, Vasodilators Drug Class, Recombinant Human B-Type Natriuretic Peptide Drug Class and Selective Aldosterone Receptor Antagonists Drug Class for the Years 2026 & 2032
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Therapy - Emergency Care Therapy and Short-Term Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 69: Germany 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Therapy - Percentage Breakdown of Value Sales for Emergency Care Therapy and Short-Term Therapy for the Years 2026 & 2032
    • TABLE 70: Germany Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Administration Route - Oral Administration Route, Intravenous Administration Route and Subcutaneous Administration Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 71: Germany 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Intravenous Administration Route and Subcutaneous Administration Route for the Years 2026 & 2032
  • ITALY
    • TABLE 72: Italy Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Drug Class - Angiotensin-Converting Enzyme Inhibitors Drug Class, Angiotensin II Receptor Blockers Drug Class, Beta-Blockers Drug Class, Diuretics Drug Class, Vasodilators Drug Class, Recombinant Human B-Type Natriuretic Peptide Drug Class and Selective Aldosterone Receptor Antagonists Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 73: Italy 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Angiotensin-Converting Enzyme Inhibitors Drug Class, Angiotensin II Receptor Blockers Drug Class, Beta-Blockers Drug Class, Diuretics Drug Class, Vasodilators Drug Class, Recombinant Human B-Type Natriuretic Peptide Drug Class and Selective Aldosterone Receptor Antagonists Drug Class for the Years 2026 & 2032
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Therapy - Emergency Care Therapy and Short-Term Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 75: Italy 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Therapy - Percentage Breakdown of Value Sales for Emergency Care Therapy and Short-Term Therapy for the Years 2026 & 2032
    • TABLE 76: Italy Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Administration Route - Oral Administration Route, Intravenous Administration Route and Subcutaneous Administration Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 77: Italy 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Intravenous Administration Route and Subcutaneous Administration Route for the Years 2026 & 2032
  • UNITED KINGDOM
    • Acute Heart Failure (AHF) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2026 (E)
    • TABLE 78: UK Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Drug Class - Angiotensin-Converting Enzyme Inhibitors Drug Class, Angiotensin II Receptor Blockers Drug Class, Beta-Blockers Drug Class, Diuretics Drug Class, Vasodilators Drug Class, Recombinant Human B-Type Natriuretic Peptide Drug Class and Selective Aldosterone Receptor Antagonists Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 79: UK 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Angiotensin-Converting Enzyme Inhibitors Drug Class, Angiotensin II Receptor Blockers Drug Class, Beta-Blockers Drug Class, Diuretics Drug Class, Vasodilators Drug Class, Recombinant Human B-Type Natriuretic Peptide Drug Class and Selective Aldosterone Receptor Antagonists Drug Class for the Years 2026 & 2032
    • TABLE 80: UK Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Therapy - Emergency Care Therapy and Short-Term Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 81: UK 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Therapy - Percentage Breakdown of Value Sales for Emergency Care Therapy and Short-Term Therapy for the Years 2026 & 2032
    • TABLE 82: UK Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Administration Route - Oral Administration Route, Intravenous Administration Route and Subcutaneous Administration Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 83: UK 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Intravenous Administration Route and Subcutaneous Administration Route for the Years 2026 & 2032
  • SPAIN
    • TABLE 84: Spain Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Drug Class - Angiotensin-Converting Enzyme Inhibitors Drug Class, Angiotensin II Receptor Blockers Drug Class, Beta-Blockers Drug Class, Diuretics Drug Class, Vasodilators Drug Class, Recombinant Human B-Type Natriuretic Peptide Drug Class and Selective Aldosterone Receptor Antagonists Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 85: Spain 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Angiotensin-Converting Enzyme Inhibitors Drug Class, Angiotensin II Receptor Blockers Drug Class, Beta-Blockers Drug Class, Diuretics Drug Class, Vasodilators Drug Class, Recombinant Human B-Type Natriuretic Peptide Drug Class and Selective Aldosterone Receptor Antagonists Drug Class for the Years 2026 & 2032
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Therapy - Emergency Care Therapy and Short-Term Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 87: Spain 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Therapy - Percentage Breakdown of Value Sales for Emergency Care Therapy and Short-Term Therapy for the Years 2026 & 2032
    • TABLE 88: Spain Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Administration Route - Oral Administration Route, Intravenous Administration Route and Subcutaneous Administration Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 89: Spain 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Intravenous Administration Route and Subcutaneous Administration Route for the Years 2026 & 2032
  • RUSSIA
    • TABLE 90: Russia Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Drug Class - Angiotensin-Converting Enzyme Inhibitors Drug Class, Angiotensin II Receptor Blockers Drug Class, Beta-Blockers Drug Class, Diuretics Drug Class, Vasodilators Drug Class, Recombinant Human B-Type Natriuretic Peptide Drug Class and Selective Aldosterone Receptor Antagonists Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 91: Russia 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Angiotensin-Converting Enzyme Inhibitors Drug Class, Angiotensin II Receptor Blockers Drug Class, Beta-Blockers Drug Class, Diuretics Drug Class, Vasodilators Drug Class, Recombinant Human B-Type Natriuretic Peptide Drug Class and Selective Aldosterone Receptor Antagonists Drug Class for the Years 2026 & 2032
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Therapy - Emergency Care Therapy and Short-Term Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 93: Russia 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Therapy - Percentage Breakdown of Value Sales for Emergency Care Therapy and Short-Term Therapy for the Years 2026 & 2032
    • TABLE 94: Russia Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Administration Route - Oral Administration Route, Intravenous Administration Route and Subcutaneous Administration Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 95: Russia 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Intravenous Administration Route and Subcutaneous Administration Route for the Years 2026 & 2032
  • REST OF EUROPE
    • TABLE 96: Rest of Europe Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Drug Class - Angiotensin-Converting Enzyme Inhibitors Drug Class, Angiotensin II Receptor Blockers Drug Class, Beta-Blockers Drug Class, Diuretics Drug Class, Vasodilators Drug Class, Recombinant Human B-Type Natriuretic Peptide Drug Class and Selective Aldosterone Receptor Antagonists Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 97: Rest of Europe 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Angiotensin-Converting Enzyme Inhibitors Drug Class, Angiotensin II Receptor Blockers Drug Class, Beta-Blockers Drug Class, Diuretics Drug Class, Vasodilators Drug Class, Recombinant Human B-Type Natriuretic Peptide Drug Class and Selective Aldosterone Receptor Antagonists Drug Class for the Years 2026 & 2032
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Therapy - Emergency Care Therapy and Short-Term Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 99: Rest of Europe 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Therapy - Percentage Breakdown of Value Sales for Emergency Care Therapy and Short-Term Therapy for the Years 2026 & 2032
    • TABLE 100: Rest of Europe Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Administration Route - Oral Administration Route, Intravenous Administration Route and Subcutaneous Administration Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 101: Rest of Europe 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Intravenous Administration Route and Subcutaneous Administration Route for the Years 2026 & 2032
  • ASIA-PACIFIC
    • Acute Heart Failure (AHF) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2026 (E)
    • TABLE 102: Asia-Pacific Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
    • TABLE 103: Asia-Pacific 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2026 & 2032
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Drug Class - Angiotensin-Converting Enzyme Inhibitors Drug Class, Angiotensin II Receptor Blockers Drug Class, Beta-Blockers Drug Class, Diuretics Drug Class, Vasodilators Drug Class, Recombinant Human B-Type Natriuretic Peptide Drug Class and Selective Aldosterone Receptor Antagonists Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 105: Asia-Pacific 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Angiotensin-Converting Enzyme Inhibitors Drug Class, Angiotensin II Receptor Blockers Drug Class, Beta-Blockers Drug Class, Diuretics Drug Class, Vasodilators Drug Class, Recombinant Human B-Type Natriuretic Peptide Drug Class and Selective Aldosterone Receptor Antagonists Drug Class for the Years 2026 & 2032
    • TABLE 106: Asia-Pacific Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Therapy - Emergency Care Therapy and Short-Term Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 107: Asia-Pacific 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Therapy - Percentage Breakdown of Value Sales for Emergency Care Therapy and Short-Term Therapy for the Years 2026 & 2032
    • TABLE 108: Asia-Pacific Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Administration Route - Oral Administration Route, Intravenous Administration Route and Subcutaneous Administration Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 109: Asia-Pacific 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Intravenous Administration Route and Subcutaneous Administration Route for the Years 2026 & 2032
  • AUSTRALIA
    • Acute Heart Failure (AHF) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2026 (E)
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Drug Class - Angiotensin-Converting Enzyme Inhibitors Drug Class, Angiotensin II Receptor Blockers Drug Class, Beta-Blockers Drug Class, Diuretics Drug Class, Vasodilators Drug Class, Recombinant Human B-Type Natriuretic Peptide Drug Class and Selective Aldosterone Receptor Antagonists Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 111: Australia 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Angiotensin-Converting Enzyme Inhibitors Drug Class, Angiotensin II Receptor Blockers Drug Class, Beta-Blockers Drug Class, Diuretics Drug Class, Vasodilators Drug Class, Recombinant Human B-Type Natriuretic Peptide Drug Class and Selective Aldosterone Receptor Antagonists Drug Class for the Years 2026 & 2032
    • TABLE 112: Australia Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Therapy - Emergency Care Therapy and Short-Term Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 113: Australia 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Therapy - Percentage Breakdown of Value Sales for Emergency Care Therapy and Short-Term Therapy for the Years 2026 & 2032
    • TABLE 114: Australia Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Administration Route - Oral Administration Route, Intravenous Administration Route and Subcutaneous Administration Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 115: Australia 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Intravenous Administration Route and Subcutaneous Administration Route for the Years 2026 & 2032
  • INDIA
    • Acute Heart Failure (AHF) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2026 (E)
    • TABLE 116: India Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Drug Class - Angiotensin-Converting Enzyme Inhibitors Drug Class, Angiotensin II Receptor Blockers Drug Class, Beta-Blockers Drug Class, Diuretics Drug Class, Vasodilators Drug Class, Recombinant Human B-Type Natriuretic Peptide Drug Class and Selective Aldosterone Receptor Antagonists Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 117: India 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Angiotensin-Converting Enzyme Inhibitors Drug Class, Angiotensin II Receptor Blockers Drug Class, Beta-Blockers Drug Class, Diuretics Drug Class, Vasodilators Drug Class, Recombinant Human B-Type Natriuretic Peptide Drug Class and Selective Aldosterone Receptor Antagonists Drug Class for the Years 2026 & 2032
    • TABLE 118: India Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Therapy - Emergency Care Therapy and Short-Term Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 119: India 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Therapy - Percentage Breakdown of Value Sales for Emergency Care Therapy and Short-Term Therapy for the Years 2026 & 2032
    • TABLE 120: India Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Administration Route - Oral Administration Route, Intravenous Administration Route and Subcutaneous Administration Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 121: India 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Intravenous Administration Route and Subcutaneous Administration Route for the Years 2026 & 2032
  • SOUTH KOREA
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Drug Class - Angiotensin-Converting Enzyme Inhibitors Drug Class, Angiotensin II Receptor Blockers Drug Class, Beta-Blockers Drug Class, Diuretics Drug Class, Vasodilators Drug Class, Recombinant Human B-Type Natriuretic Peptide Drug Class and Selective Aldosterone Receptor Antagonists Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 123: South Korea 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Angiotensin-Converting Enzyme Inhibitors Drug Class, Angiotensin II Receptor Blockers Drug Class, Beta-Blockers Drug Class, Diuretics Drug Class, Vasodilators Drug Class, Recombinant Human B-Type Natriuretic Peptide Drug Class and Selective Aldosterone Receptor Antagonists Drug Class for the Years 2026 & 2032
    • TABLE 124: South Korea Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Therapy - Emergency Care Therapy and Short-Term Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 125: South Korea 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Therapy - Percentage Breakdown of Value Sales for Emergency Care Therapy and Short-Term Therapy for the Years 2026 & 2032
    • TABLE 126: South Korea Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Administration Route - Oral Administration Route, Intravenous Administration Route and Subcutaneous Administration Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 127: South Korea 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Intravenous Administration Route and Subcutaneous Administration Route for the Years 2026 & 2032
  • REST OF ASIA-PACIFIC
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Drug Class - Angiotensin-Converting Enzyme Inhibitors Drug Class, Angiotensin II Receptor Blockers Drug Class, Beta-Blockers Drug Class, Diuretics Drug Class, Vasodilators Drug Class, Recombinant Human B-Type Natriuretic Peptide Drug Class and Selective Aldosterone Receptor Antagonists Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 129: Rest of Asia-Pacific 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Angiotensin-Converting Enzyme Inhibitors Drug Class, Angiotensin II Receptor Blockers Drug Class, Beta-Blockers Drug Class, Diuretics Drug Class, Vasodilators Drug Class, Recombinant Human B-Type Natriuretic Peptide Drug Class and Selective Aldosterone Receptor Antagonists Drug Class for the Years 2026 & 2032
    • TABLE 130: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Therapy - Emergency Care Therapy and Short-Term Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 131: Rest of Asia-Pacific 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Therapy - Percentage Breakdown of Value Sales for Emergency Care Therapy and Short-Term Therapy for the Years 2026 & 2032
    • TABLE 132: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Administration Route - Oral Administration Route, Intravenous Administration Route and Subcutaneous Administration Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Intravenous Administration Route and Subcutaneous Administration Route for the Years 2026 & 2032
  • LATIN AMERICA
    • Acute Heart Failure (AHF) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2026 (E)
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
    • TABLE 135: Latin America 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2026 & 2032
    • TABLE 136: Latin America Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Drug Class - Angiotensin-Converting Enzyme Inhibitors Drug Class, Angiotensin II Receptor Blockers Drug Class, Beta-Blockers Drug Class, Diuretics Drug Class, Vasodilators Drug Class, Recombinant Human B-Type Natriuretic Peptide Drug Class and Selective Aldosterone Receptor Antagonists Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 137: Latin America 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Angiotensin-Converting Enzyme Inhibitors Drug Class, Angiotensin II Receptor Blockers Drug Class, Beta-Blockers Drug Class, Diuretics Drug Class, Vasodilators Drug Class, Recombinant Human B-Type Natriuretic Peptide Drug Class and Selective Aldosterone Receptor Antagonists Drug Class for the Years 2026 & 2032
    • TABLE 138: Latin America Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Therapy - Emergency Care Therapy and Short-Term Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 139: Latin America 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Therapy - Percentage Breakdown of Value Sales for Emergency Care Therapy and Short-Term Therapy for the Years 2026 & 2032
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Administration Route - Oral Administration Route, Intravenous Administration Route and Subcutaneous Administration Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 141: Latin America 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Intravenous Administration Route and Subcutaneous Administration Route for the Years 2026 & 2032
  • ARGENTINA
    • TABLE 142: Argentina Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Drug Class - Angiotensin-Converting Enzyme Inhibitors Drug Class, Angiotensin II Receptor Blockers Drug Class, Beta-Blockers Drug Class, Diuretics Drug Class, Vasodilators Drug Class, Recombinant Human B-Type Natriuretic Peptide Drug Class and Selective Aldosterone Receptor Antagonists Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 143: Argentina 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Angiotensin-Converting Enzyme Inhibitors Drug Class, Angiotensin II Receptor Blockers Drug Class, Beta-Blockers Drug Class, Diuretics Drug Class, Vasodilators Drug Class, Recombinant Human B-Type Natriuretic Peptide Drug Class and Selective Aldosterone Receptor Antagonists Drug Class for the Years 2026 & 2032
    • TABLE 144: Argentina Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Therapy - Emergency Care Therapy and Short-Term Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 145: Argentina 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Therapy - Percentage Breakdown of Value Sales for Emergency Care Therapy and Short-Term Therapy for the Years 2026 & 2032
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Administration Route - Oral Administration Route, Intravenous Administration Route and Subcutaneous Administration Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 147: Argentina 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Intravenous Administration Route and Subcutaneous Administration Route for the Years 2026 & 2032
  • BRAZIL
    • TABLE 148: Brazil Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Drug Class - Angiotensin-Converting Enzyme Inhibitors Drug Class, Angiotensin II Receptor Blockers Drug Class, Beta-Blockers Drug Class, Diuretics Drug Class, Vasodilators Drug Class, Recombinant Human B-Type Natriuretic Peptide Drug Class and Selective Aldosterone Receptor Antagonists Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 149: Brazil 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Angiotensin-Converting Enzyme Inhibitors Drug Class, Angiotensin II Receptor Blockers Drug Class, Beta-Blockers Drug Class, Diuretics Drug Class, Vasodilators Drug Class, Recombinant Human B-Type Natriuretic Peptide Drug Class and Selective Aldosterone Receptor Antagonists Drug Class for the Years 2026 & 2032
    • TABLE 150: Brazil Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Therapy - Emergency Care Therapy and Short-Term Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 151: Brazil 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Therapy - Percentage Breakdown of Value Sales for Emergency Care Therapy and Short-Term Therapy for the Years 2026 & 2032
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Administration Route - Oral Administration Route, Intravenous Administration Route and Subcutaneous Administration Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 153: Brazil 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Intravenous Administration Route and Subcutaneous Administration Route for the Years 2026 & 2032
  • MEXICO
    • TABLE 154: Mexico Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Drug Class - Angiotensin-Converting Enzyme Inhibitors Drug Class, Angiotensin II Receptor Blockers Drug Class, Beta-Blockers Drug Class, Diuretics Drug Class, Vasodilators Drug Class, Recombinant Human B-Type Natriuretic Peptide Drug Class and Selective Aldosterone Receptor Antagonists Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 155: Mexico 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Angiotensin-Converting Enzyme Inhibitors Drug Class, Angiotensin II Receptor Blockers Drug Class, Beta-Blockers Drug Class, Diuretics Drug Class, Vasodilators Drug Class, Recombinant Human B-Type Natriuretic Peptide Drug Class and Selective Aldosterone Receptor Antagonists Drug Class for the Years 2026 & 2032
    • TABLE 156: Mexico Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Therapy - Emergency Care Therapy and Short-Term Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 157: Mexico 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Therapy - Percentage Breakdown of Value Sales for Emergency Care Therapy and Short-Term Therapy for the Years 2026 & 2032
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Administration Route - Oral Administration Route, Intravenous Administration Route and Subcutaneous Administration Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 159: Mexico 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Intravenous Administration Route and Subcutaneous Administration Route for the Years 2026 & 2032
  • REST OF LATIN AMERICA
    • TABLE 160: Rest of Latin America Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Drug Class - Angiotensin-Converting Enzyme Inhibitors Drug Class, Angiotensin II Receptor Blockers Drug Class, Beta-Blockers Drug Class, Diuretics Drug Class, Vasodilators Drug Class, Recombinant Human B-Type Natriuretic Peptide Drug Class and Selective Aldosterone Receptor Antagonists Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 161: Rest of Latin America 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Angiotensin-Converting Enzyme Inhibitors Drug Class, Angiotensin II Receptor Blockers Drug Class, Beta-Blockers Drug Class, Diuretics Drug Class, Vasodilators Drug Class, Recombinant Human B-Type Natriuretic Peptide Drug Class and Selective Aldosterone Receptor Antagonists Drug Class for the Years 2026 & 2032
    • TABLE 162: Rest of Latin America Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Therapy - Emergency Care Therapy and Short-Term Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 163: Rest of Latin America 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Therapy - Percentage Breakdown of Value Sales for Emergency Care Therapy and Short-Term Therapy for the Years 2026 & 2032
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Administration Route - Oral Administration Route, Intravenous Administration Route and Subcutaneous Administration Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 165: Rest of Latin America 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Intravenous Administration Route and Subcutaneous Administration Route for the Years 2026 & 2032
  • MIDDLE EAST
    • Acute Heart Failure (AHF) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2026 (E)
    • TABLE 166: Middle East Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
    • TABLE 167: Middle East 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2026 & 2032
    • TABLE 168: Middle East Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Drug Class - Angiotensin-Converting Enzyme Inhibitors Drug Class, Angiotensin II Receptor Blockers Drug Class, Beta-Blockers Drug Class, Diuretics Drug Class, Vasodilators Drug Class, Recombinant Human B-Type Natriuretic Peptide Drug Class and Selective Aldosterone Receptor Antagonists Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 169: Middle East 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Angiotensin-Converting Enzyme Inhibitors Drug Class, Angiotensin II Receptor Blockers Drug Class, Beta-Blockers Drug Class, Diuretics Drug Class, Vasodilators Drug Class, Recombinant Human B-Type Natriuretic Peptide Drug Class and Selective Aldosterone Receptor Antagonists Drug Class for the Years 2026 & 2032
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Therapy - Emergency Care Therapy and Short-Term Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 171: Middle East 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Therapy - Percentage Breakdown of Value Sales for Emergency Care Therapy and Short-Term Therapy for the Years 2026 & 2032
    • TABLE 172: Middle East Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Administration Route - Oral Administration Route, Intravenous Administration Route and Subcutaneous Administration Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 173: Middle East 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Intravenous Administration Route and Subcutaneous Administration Route for the Years 2026 & 2032
  • IRAN
    • TABLE 174: Iran Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Drug Class - Angiotensin-Converting Enzyme Inhibitors Drug Class, Angiotensin II Receptor Blockers Drug Class, Beta-Blockers Drug Class, Diuretics Drug Class, Vasodilators Drug Class, Recombinant Human B-Type Natriuretic Peptide Drug Class and Selective Aldosterone Receptor Antagonists Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 175: Iran 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Angiotensin-Converting Enzyme Inhibitors Drug Class, Angiotensin II Receptor Blockers Drug Class, Beta-Blockers Drug Class, Diuretics Drug Class, Vasodilators Drug Class, Recombinant Human B-Type Natriuretic Peptide Drug Class and Selective Aldosterone Receptor Antagonists Drug Class for the Years 2026 & 2032
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Therapy - Emergency Care Therapy and Short-Term Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 177: Iran 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Therapy - Percentage Breakdown of Value Sales for Emergency Care Therapy and Short-Term Therapy for the Years 2026 & 2032
    • TABLE 178: Iran Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Administration Route - Oral Administration Route, Intravenous Administration Route and Subcutaneous Administration Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 179: Iran 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Intravenous Administration Route and Subcutaneous Administration Route for the Years 2026 & 2032
  • ISRAEL
    • TABLE 180: Israel Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Drug Class - Angiotensin-Converting Enzyme Inhibitors Drug Class, Angiotensin II Receptor Blockers Drug Class, Beta-Blockers Drug Class, Diuretics Drug Class, Vasodilators Drug Class, Recombinant Human B-Type Natriuretic Peptide Drug Class and Selective Aldosterone Receptor Antagonists Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 181: Israel 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Angiotensin-Converting Enzyme Inhibitors Drug Class, Angiotensin II Receptor Blockers Drug Class, Beta-Blockers Drug Class, Diuretics Drug Class, Vasodilators Drug Class, Recombinant Human B-Type Natriuretic Peptide Drug Class and Selective Aldosterone Receptor Antagonists Drug Class for the Years 2026 & 2032
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Therapy - Emergency Care Therapy and Short-Term Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 183: Israel 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Therapy - Percentage Breakdown of Value Sales for Emergency Care Therapy and Short-Term Therapy for the Years 2026 & 2032
    • TABLE 184: Israel Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Administration Route - Oral Administration Route, Intravenous Administration Route and Subcutaneous Administration Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 185: Israel 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Intravenous Administration Route and Subcutaneous Administration Route for the Years 2026 & 2032
  • SAUDI ARABIA
    • TABLE 186: Saudi Arabia Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Drug Class - Angiotensin-Converting Enzyme Inhibitors Drug Class, Angiotensin II Receptor Blockers Drug Class, Beta-Blockers Drug Class, Diuretics Drug Class, Vasodilators Drug Class, Recombinant Human B-Type Natriuretic Peptide Drug Class and Selective Aldosterone Receptor Antagonists Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 187: Saudi Arabia 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Angiotensin-Converting Enzyme Inhibitors Drug Class, Angiotensin II Receptor Blockers Drug Class, Beta-Blockers Drug Class, Diuretics Drug Class, Vasodilators Drug Class, Recombinant Human B-Type Natriuretic Peptide Drug Class and Selective Aldosterone Receptor Antagonists Drug Class for the Years 2026 & 2032
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Therapy - Emergency Care Therapy and Short-Term Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 189: Saudi Arabia 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Therapy - Percentage Breakdown of Value Sales for Emergency Care Therapy and Short-Term Therapy for the Years 2026 & 2032
    • TABLE 190: Saudi Arabia Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Administration Route - Oral Administration Route, Intravenous Administration Route and Subcutaneous Administration Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 191: Saudi Arabia 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Intravenous Administration Route and Subcutaneous Administration Route for the Years 2026 & 2032
  • UNITED ARAB EMIRATES
    • TABLE 192: UAE Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Drug Class - Angiotensin-Converting Enzyme Inhibitors Drug Class, Angiotensin II Receptor Blockers Drug Class, Beta-Blockers Drug Class, Diuretics Drug Class, Vasodilators Drug Class, Recombinant Human B-Type Natriuretic Peptide Drug Class and Selective Aldosterone Receptor Antagonists Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 193: UAE 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Angiotensin-Converting Enzyme Inhibitors Drug Class, Angiotensin II Receptor Blockers Drug Class, Beta-Blockers Drug Class, Diuretics Drug Class, Vasodilators Drug Class, Recombinant Human B-Type Natriuretic Peptide Drug Class and Selective Aldosterone Receptor Antagonists Drug Class for the Years 2026 & 2032
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Therapy - Emergency Care Therapy and Short-Term Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 195: UAE 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Therapy - Percentage Breakdown of Value Sales for Emergency Care Therapy and Short-Term Therapy for the Years 2026 & 2032
    • TABLE 196: UAE Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Administration Route - Oral Administration Route, Intravenous Administration Route and Subcutaneous Administration Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 197: UAE 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Intravenous Administration Route and Subcutaneous Administration Route for the Years 2026 & 2032
  • REST OF MIDDLE EAST
    • TABLE 198: Rest of Middle East Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Drug Class - Angiotensin-Converting Enzyme Inhibitors Drug Class, Angiotensin II Receptor Blockers Drug Class, Beta-Blockers Drug Class, Diuretics Drug Class, Vasodilators Drug Class, Recombinant Human B-Type Natriuretic Peptide Drug Class and Selective Aldosterone Receptor Antagonists Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 199: Rest of Middle East 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Angiotensin-Converting Enzyme Inhibitors Drug Class, Angiotensin II Receptor Blockers Drug Class, Beta-Blockers Drug Class, Diuretics Drug Class, Vasodilators Drug Class, Recombinant Human B-Type Natriuretic Peptide Drug Class and Selective Aldosterone Receptor Antagonists Drug Class for the Years 2026 & 2032
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Therapy - Emergency Care Therapy and Short-Term Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 201: Rest of Middle East 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Therapy - Percentage Breakdown of Value Sales for Emergency Care Therapy and Short-Term Therapy for the Years 2026 & 2032
    • TABLE 202: Rest of Middle East Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Administration Route - Oral Administration Route, Intravenous Administration Route and Subcutaneous Administration Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 203: Rest of Middle East 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Intravenous Administration Route and Subcutaneous Administration Route for the Years 2026 & 2032
  • AFRICA
    • Acute Heart Failure (AHF) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2026 (E)
    • TABLE 204: Africa Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Drug Class - Angiotensin-Converting Enzyme Inhibitors Drug Class, Angiotensin II Receptor Blockers Drug Class, Beta-Blockers Drug Class, Diuretics Drug Class, Vasodilators Drug Class, Recombinant Human B-Type Natriuretic Peptide Drug Class and Selective Aldosterone Receptor Antagonists Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 205: Africa 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Angiotensin-Converting Enzyme Inhibitors Drug Class, Angiotensin II Receptor Blockers Drug Class, Beta-Blockers Drug Class, Diuretics Drug Class, Vasodilators Drug Class, Recombinant Human B-Type Natriuretic Peptide Drug Class and Selective Aldosterone Receptor Antagonists Drug Class for the Years 2026 & 2032
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Therapy - Emergency Care Therapy and Short-Term Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 207: Africa 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Therapy - Percentage Breakdown of Value Sales for Emergency Care Therapy and Short-Term Therapy for the Years 2026 & 2032
    • TABLE 208: Africa Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Administration Route - Oral Administration Route, Intravenous Administration Route and Subcutaneous Administration Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 209: Africa 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Intravenous Administration Route and Subcutaneous Administration Route for the Years 2026 & 2032

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!